复发脑肿瘤挽救性切除联合术中铯-131近距离放疗
该回顾性单中心研究纳入2016至2020年36例患者共40次铯-131植入治疗42个复发脑肿瘤,中位影像随访17.0个月。全队列1年局部控制率91.6%,1年总生存率82.7%,症状性放射性不良事件发生率9.5%,手术并发症率16.7%。作者认为对于经重度预处理人群,该方案局部控制良好且毒性可接受。
要点
- 全队列1年局部/局部区域/颅内控制率分别为91.6%/83.4%/47.9%。
- 全队列1年总生存率82.7%,中位生存26.7个月。
- 症状性放射性不良事件发生率9.5%,手术并发症率16.7%。
核心结论
- 铯-131近距离放疗在该经重度预处理队列中取得良好的局部控制,症状性放射性不良事件和手术并发症发生率可接受。
- 作者认为对于该患者人群,铯-131近距离放疗可能是合理的挽救性辅助治疗。
研究设计与样本
- 回顾性病历 review,连续纳入单中心接受术中颅内铯-131近距离放疗的患者。
- 最大范围安全切除肿瘤后,将永久性缝线串铯-131粒子植入切除腔。
- 2016年至2020年间,36例患者接受40次连续铯-131植入,治疗42个复发脑肿瘤,中位影像随访17.0个月(IQR 12.7-25.9)。
主要发现
- 20例患者(55.6%)共22次植入治疗复发脑转移瘤,12例(33.3%)共16次植入治疗复发非典型(n=7)或间变性(n=5)脑膜瘤,4例(11.1%)治疗其他复发原发性脑肿瘤。
- 除1个肿瘤(97.6%)外,所有肿瘤均接受过既往放疗,其中20个(47.6%)接受过2次或以上既往放疗,23个(54.8%)接受过既往切除。
- 中位肿瘤大小3.0 cm(IQR 2.3-3.7),17个病灶(40.5%)在挽救治疗前有放射性不良事件的影像学证据。
- 全队列及转移瘤和脑膜瘤患者的1年局部/局部区域/颅内控制率分别为91.6%/83.4%/47.9%、88.8%/84.4%/45.4%和100%/83.9%/46.4%。
- 全队列及转移瘤和脑膜瘤患者的1年总生存率分别为82.7%、79.1%和91.7%,所有患者中位生存26.7个月(IQR 15.6-36.4)。
关键数值与推荐
- 全队列1年局部控制率91.6%,局部区域控制率83.4%,颅内控制率47.9%。
- 全队列1年总生存率82.7%,中位生存26.7个月(IQR 15.6-36.4)。
- 7例患者(19.4%)死于颅内疾病进展导致的神经性死亡(占14例总死亡的50%),其中5例(13.9%)死于软脑膜疾病。
- 症状性放射性不良事件见于9.5%的切除腔(n=4),其中1例(2.4%)为3级。
- 手术并发症率16.7%(n=7),其中4例(9.5%)为3级或以上并发症,包括1例(2.4%)围手术期死亡。
临床怎么用
- 作者认为铯-131近距离放疗可能是该经重度预处理复发脑肿瘤人群合理的挽救性辅助治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The authors' objective was to examine the safety and efficacy of salvage intracranial cesium-131 brachytherapy in combination with resection of recurrent brain tumors. METHODS: The authors conducted a retrospective chart review of consecutive patients treated with intraoperative intracranial cesium-131 brachytherapy at a single institution. Permanent suture-stranded cesium-131 seeds were implanted in the resection cavity after maximal safe tumor resection. The primary outcomes of interest were local, locoregional (within 1 cm), and intracranial control, as well as rates of overall survival (OS), neurological death, symptomatic adverse radiation effects (AREs), and surgical complication rate graded according to Common Terminology Criteria for Adverse Events version 5.0. RESULTS: Between 2016 and 2020, 36 patients received 40 consecutive cesium-131 implants for 42 recurrent brain tumors and received imaging follow-up for a median (interquartile range [IQR]) of 17.0 (12.7-25.9) months. Twenty patients (55.6%) with 22 implants were treated for recurrent brain metastasis, 12 patients (33.3%) with 16 implants were treated for recurrent atypical (n = 7) or anaplastic (n = 5) meningioma, and 4 patients (11.1%) were treated for other recurrent primary brain neoplasms. All except 1 tumor (97.6%) had received prior radiotherapy, including 20 (47.6%) that underwent 2 or more prior radiotherapy treatments and 23 (54.8%) that underwent prior resection. The median (IQR) tumor size was 3.0 (2.3-3.7) cm, and 17 lesions (40.5%) had radiographic evidence of ARE prior to salvage therapy. Actuarial 1-year local/locoregional/intracranial control rates for the whole cohort and patients with metastases and meningiomas were 91.6%/83.4%/47.9%, 88.8%/84.4%/45.4%, and 100%/83.9%/46.4%, respectively. No cases of local recurrence of any histology (0 of 27) occurred after gross-total resection (p = 0.012, log-rank test). The 1-year OS rates for the whole cohort and patients with metastases and meningiomas were 82.7%, 79.1%, and 91.7%, respectively, and the median (IQR) survival of all patients was 26.7 (15.6-36.4) months. Seven patients (19.4%) experienced neurological death from progressive intracranial disease (7 of 14 total deaths [50%]), 5 (13.9%) of whom died of leptomeningeal disease. Symptomatic AREs were observed in 9.5% of resection cavities (n = 4), of which 1 (2.4%) was grade 3 in severity. The surgical complication rate was 16.7% (n = 7); 4 (9.5%) of these patients had grade 3 or higher complications, including 1 patient (2.4%) who died perioperatively. CONCLUSIONS: Cesium-131 brachytherapy resulted in good local control and acceptable rates of symptomatic AREs and surgical complications in this heavily pretreated cohort, and it may be a reasonable salvage adjuvant treatment for this patient population.
引用
- Chen WC, Lafreniere M, Phuong C, et al. Resection with intraoperative cesium-131 brachytherapy as salvage therapy for recurrent brain tumors. J Neurosurg. 2022. PMID: 35061986. doi:10.3171/2021.10.JNS211886
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。